Healthcare - Press Releases

Date	Title	Company
31-Mar-2021	National Horizons Centre expands as National Training Centre for the Advanced Therapies Skills Training Network (ATSTN)	National Horizons Centre
31-Mar-2021	‘COVID-friendly’ cancer care at home extended for more patients	NHS England
31-Mar-2021	Recombinant Vaccine Market is estimated to Grow at the Highest Growth Rate till 2020-2027	Value Market Research
31-Mar-2021	Point-Of-Care Cholesterol Monitoring Device Market To Set Phenomenal Growth In Key Regions By 2020–2027	Value Market Research
30-Mar-2021	Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody	Tiziana Life Sciences plc
30-Mar-2021	China Medical System (00867) Ushers in a Revaluation with its Continuous Growth and Synergy between Innovative Business and New Businesses	ACN Newswire
30-Mar-2021	Sputnik V vaccine authorized in Mali	Russian Direct Investment Fund
30-Mar-2021	Higher Orange Consumption Linked To Increased Risk of Melanoma, New Study Suggests	UK Biobank
30-Mar-2021	Blood Coagulation Factor Market growth insight & trend analysis 2021	Profshare Market research
30-Mar-2021	Antiemetics Market likely to reach USD 7502.21 million by end of 2028	Profshare Market research
30-Mar-2021	GSK to support manufacture of Novavax’ COVID-19 vaccine	GSK
30-Mar-2021	Moderna Announces Shipment of 100 Millionth Dose of its COVID-19 Vaccine to the U.S. Government	Moderna
30-Mar-2021	Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 Vaccine Candidate	Johnson & Johnson
29-Mar-2021	gaitQ Awarded Grant by the UK’s National Institute for Health Research for the continued development of its system	gaitQ
29-Mar-2021	Instant Covid Tests London to launch first test centre using 20-second Virolens technology	Instant Covid Tests London (ICTL)
29-Mar-2021	Syncona cornerstones $148 million Series C Financing in Gyroscope	Syncona Ltd
29-Mar-2021	Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation	Vertex Pharmaceuticals Incorporated
29-Mar-2021	Gadopiclenol: positive results for Phase III clinical trials	Guerbet
29-Mar-2021	Avifavir obtains its first registration in Asia	Russian Direct Investment Fund
29-Mar-2021	PrecisionLife continues growth and expansion with acquisition of Danish genomic analytics innovator GenoKey	PrecisionLife